Supriya Lifescience Expands Production to Strengthen Market Position

Supriya Lifescience's new plant is anticipated to improve production capabilities, aiding its expansion in the competitive pharmaceutical sector. Pharma shares experienced a 6 percent rise after the launch of a modern E-Production Block in Maharashtra, involving an investment of Rs.125 crore.

The pharmaceutical company has broadened its activities with the opening of a new multifunctional Active Pharmaceutical Ingredients (APIs) manufacturing block, Module E, at the Lote Parshuram location. The newly constructed facility, covering 5,000 square meters and developed over four floors, guarantees effective operations and secure workflows. It has 33 reactors, featuring both stainless steel and glass-lined types, with capacities from 1.6 KL to 16 KL.

The design utilizes gravity-driven process flows to enhance safety, preserve product integrity, and maximize overall efficiency. During Wednesday’s trading session, the share price of Supriya Lifescience Ltd jumped 6 percent, reaching an intra-day peak of Rs.758.50 per share, rising from the previous close of Rs.717.25 per share. The price has since decreased and is now trading at Rs.748.90 for each share. In the last year, the stocks have provided more than 170 percent returns.

Supriya Lifescience Limited, based in Mumbai, India, is a publicly traded generic pharmaceutical firm founded in 1987, focused on creating and marketing APIs and FDFs for treating patients with diverse diseases and infections.